ClinicalTrials.gg
TerminatedNCT01509053ARRIVE- EUUpdated Mar 4, 2015Results posted

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

A Phase 3 interventional study of Aripiprazole (Abilify®) IM Depot Injection and Oral aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-04.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
103rd of 125
30 · median 130
Started
2012
with 3 others
Phase 3
34 of 126
1 open now
Registered
71st of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 103rd largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 34 in phase 3, and was the 71st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.

Read the detailed description

Nonadherence to antipsychotic medications remains a frequent cause of relapse among patients with schizophrenia, increasing hospitalization rates, hospitalization days, and hospitalization costs. Among hospitalized adults, schizophrenia is the fourth most commonly diagnosed illness and has the seventh longest mean duration of hospital stay in the US. Frequent relapses and hospitalization can affect quality of life in these patients. Long-acting injections (intramuscular depot) antipsychotic medication is a means to treatment adherence and increased quality of life for patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written . If the Institutional Review Board (IRB) requires consent by a legally acceptable representative in addition to the subject, all required consents must be obtained prior to any protocol-required procedure.
  • Male and female subjects 18 to 65 years of age, inclusive
  • Current diagnosis of schizophrenia as defined by (DSM-IV-TR) criteria and a history of the illness for at least 1 year (12 months)
  • Subjects who in the investigator's judgment would benefit from extended treatment with a long-acting injectable formulation
  • Subjects who have at least 1 inpatient psychiatric hospitalization in the 2 years (24 months) prior to screening, but have been managed as outpatients for the 4 weeks prior entering the study
  • Subjects must have been on oral antipsychotic treatment for the full 7 months prior to the screening phase Subjects who have shown response to previous antipsychotic treatment.
  • Subjects who understand the nature of the trial and are able to follow the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated), or have been incarcerated in the past 7 months for any reason must not be enrolled into this trial.
  • Subjects who may require potent CYP2D6 or inhibitors or CYP3A4 inducers during the trial.
  • Any subject who requires or may need any other antipsychotic medications during the course of the trial, other than allowed rescue medication.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
  • Subjects with a history of to antipsychotic agents.
  • Subjects deemed intolerant of receiving injectable treatment.
  • Subjects who have received electroconvulsive therapy within the last 7 months prior to screening.
  • Subjects with a history of neuroleptic malignant syndrome or tardive dyskinesia as assessed by the investigator.
  • Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects requiring hospitalization for any psychiatric reason during the 4 weeks prior to signing the Form (ICF) or during the screening period.
  • Subjects without at least 1 inpatient psychiatric hospitalization in the last 2 years (24 months) prior to screening.
  • Subjects who have met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening.
  • Subjects who are considered treatment-resistant to antipsychotic medication other than clozapine.
  • Treatment with long-acting injectable antipsychotics in which the last dose was within 7 months prior to screening.
  • Subjects who have not been treated with oral antipsychotics for 7 months prior to screening.
  • Subjects who have a significant risk of committing suicide
  • Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Sexually active males and females who will not commit to utilizing during the trial and for up to 180 days following the trial.
  • Abnormal laboratory or physical examination results indicating a condition which may interfere with the results of the study or pose a safety risk to the subject.
  • Subjects who have previously enrolled in an aripiprazole IM depot clinical study or who have participated in any clinical trial with an agent within the past 30 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Aripiprazole IM depot injection

    Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.

    Drug: Aripiprazole (Abilify®) IM Depot Injection · Drug: Oral aripiprazole

Interventions

  • 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg. Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.

    Also known as: ABILIFY®

  • Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).

06

What researchers measure

Primary outcomes

  1. Comparison of Inpatient Psychiatric Hospitalization Rates

    The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥1 inpatient psychiatric hospitalizations) between the retrospective period Months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B Months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot.

    Time frame: Retrospective period Months 4-6; Prospective period Months 4-6

Secondary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 24

  2. Change From Baseline in PANSS Positive and Negative Subscale Scores

    The PANSS Positive Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. The PANSS Negative Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 24

  3. Clinical Global Impression of Severity (CGI-S) Score

    The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients.

    Time frame: Baseline, Week 24

  4. Clinical Global Impression of Improvement (CGI-I) Score

    The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.

    Time frame: Baseline, Week 24

07

Results

Posted Jan 16, 2014

Participant flow

Oral Aripirazole (Phase A)
Participant flow — Oral Aripirazole (Phase A)
MilestoneOral Aripiprazole Tablets and Aripiprazole IM Depot Injection
Started19
Completed8
Not completed11
Withdrew: Sponsor discontinued study11
Aripiprazole IM Depot Treatment Phase(B)
Participant flow — Aripiprazole IM Depot Treatment Phase(B)
MilestoneOral Aripiprazole Tablets and Aripiprazole IM Depot Injection
Started19
Completed3
Not completed16
Withdrew: Adverse event1
Withdrew: Sponsor discontinued study13
Withdrew: Subject was withdrawn by investigator1
Withdrew: Subject withdrew consent1
Aripiprazole IM Depot Extension Phase(C)
Participant flow — Aripiprazole IM Depot Extension Phase(C)
MilestoneOral Aripiprazole Tablets and Aripiprazole IM Depot Injection
Started3
Completed0
Not completed3
Withdrew: Sponsor discontinued study3

Outcome measures

PrimaryComparison of Inpatient Psychiatric Hospitalization Rates

The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥1 inpatient psychiatric hospitalizations) between the retrospective period Months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B Months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot.

Time frame:
Retrospective period Months 4-6; Prospective period Months 4-6

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of 3 subscales with a total of 30 symptom constructs each rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The Positive Subscale consisted of 7 positive symptom constructs with a possible subscale score of 7 to 49, the Negative Subscale consisted of 7 negative symptom constructs with a possible subscale score of 7 to 49 and the General Psychopathology Subscale consisted of 16 symptom constructs for a possible subscale score of 16 to 112. The PANSS Total Score ranged from 30 (best) to 210 (worst; indicating more severe symptoms). A Negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in PANSS Positive and Negative Subscale Scores

The PANSS Positive Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Positive Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. The PANSS Negative Subscale consisted of 7 symptom constructs rated on a 7-point scale where 1=absence of symptoms to 7=extremely severe symptoms. The total score on the Negative Subscale ranged from 7 to 49 with a higher score indicating more severe symptoms. A Negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryClinical Global Impression of Severity (CGI-S) Score

The severity of illness for each participant was rated using the CGI-S scale. The investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" using an 8-point scale where 0=not assessed to 7=among the most extremely ill patients.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryClinical Global Impression of Improvement (CGI-I) Score

The participant's overall improvement was rated for each participant using the CGI-I scale. The investigator rated the participant's total improvement by answering the following question: "Compared to his/her condition at baseline (prior to randomization), how much has the patient changed?" using an 8-point scale where 0=not assessed, 1=very much improved to 7=very much worse. Lower scores indicated improvement.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Aripiprazole (Phase A)—0/19 (0%)4/19 (21.1%)
Aripiprazole IM Depot (Phase B)—1/19 (5.3%)10/19 (52.6%)
Aripiprazole IM Depot (Phase C)—0/3 (0%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventOral Aripiprazole (Phase A)Aripiprazole IM Depot (Phase B)Aripiprazole IM Depot (Phase C)
Drug-induced liver injuryHepatobiliary disorders0/191/190/3
SchizophreniaPsychiatric disorders0/191/190/3
Most frequent other events
Showing 10 of 18
Most frequent other events
EventOral Aripiprazole (Phase A)Aripiprazole IM Depot (Phase B)Aripiprazole IM Depot (Phase C)
Diabetes mellitusMetabolism and nutrition disorders0/191/191/3
InsomniaPsychiatric disorders3/193/190/3
FatigueGeneral disorders1/192/190/3
FlatulenceGastrointestinal disorders0/191/190/3
IrritabilityGeneral disorders0/191/190/3
BronchitisInfections and infestations0/191/190/3
Alanine aminotransferase increasedInvestigations0/191/190/3
Aspartate aminotransferase increasedInvestigations0/191/190/3
Blood creatine phosphokinase increasedInvestigations0/191/190/3
Blood glucose increasedInvestigations0/191/190/3

Baseline characteristics

Baseline measures are based on all enrolled participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean43.9 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male20
08

Study locations

10 sites
  • Brugge, 8310, Belgium
  • Bruxelles, 1160, Belgium
  • Kortenberg, 3070, Belgium
  • Liège, 4000, Belgium
  • Lovech, 5500, Bulgaria
  • Novi Iskar, 1282, Bulgaria
  • Pazardjik, 4400, Bulgaria
  • Tzerova Koria, 5047, Bulgaria
  • Penticton, British Columbia V2A 4M4, Canada
  • Chatham, Ontario N7M 5L9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2011
First posted
Jan 12, 2012
Start
Jan 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Jan 16, 2014
Last update
Mar 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01509053
Responsible party
Sponsor
First posted
Jan 12, 2012
Start date
Jan 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Jan 16, 2014
Last update
Mar 4, 2015

Study contacts

Tim Peters-Strickland
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion